Cogent Biosciences, Inc. last reported quarterly results on Aug 10, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.52. It usually reports 34–48 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 2, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Monday. Based on last year's release for the same quarter on Nov 3, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–48 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-96
-31.1%
|
-0.52
+1.9%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-97
-35.2%
|
-0.53
-1.9%
|
|
Feb 17, 2026
48 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-102
-50.9%
|
-0.68
-11.9%
|
|
Nov 3, 2025
34 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-81
-14.6%
|
-0.50
+3.8%
|
|
Jul 10, 2025
10 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-74
-24.7%
|
-0.53
-23.3%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-72
-23.4%
|
-0.52
-6.1%
|
|
Feb 25, 2025
56 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-68
-24.9%
|
-0.61
+2.4%
|
|
Nov 12, 2024
43 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COGT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1622229
- Former names
- Unum Therapeutics Inc. (until Oct 5, 2020); Unum Therapeutics, Inc. (until Mar 30, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.